GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InVivo Therapeutics Holdings Corp (OTCPK:NVIVQ) » Definitions » Liabilities-to-Assets

InVivo Therapeutics Holdings (InVivo Therapeutics Holdings) Liabilities-to-Assets : 0.07 (As of Sep. 2023)


View and export this data going back to 2010. Start your Free Trial

What is InVivo Therapeutics Holdings Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. InVivo Therapeutics Holdings's Total Liabilities for the quarter that ended in Sep. 2023 was $0.67 Mil. InVivo Therapeutics Holdings's Total Assets for the quarter that ended in Sep. 2023 was $9.58 Mil. Therefore, InVivo Therapeutics Holdings's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2023 was 0.07.


InVivo Therapeutics Holdings Liabilities-to-Assets Historical Data

The historical data trend for InVivo Therapeutics Holdings's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InVivo Therapeutics Holdings Liabilities-to-Assets Chart

InVivo Therapeutics Holdings Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.12 0.40 0.12 0.17 0.16

InVivo Therapeutics Holdings Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.16 0.14 0.13 0.07

Competitive Comparison of InVivo Therapeutics Holdings's Liabilities-to-Assets

For the Biotechnology subindustry, InVivo Therapeutics Holdings's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InVivo Therapeutics Holdings's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InVivo Therapeutics Holdings's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where InVivo Therapeutics Holdings's Liabilities-to-Assets falls into.



InVivo Therapeutics Holdings Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

InVivo Therapeutics Holdings's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Liabilities-to-Assets (A: Dec. 2022 )=Total Liabilities/Total Assets
=3.076/18.822
=0.16

InVivo Therapeutics Holdings's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2023 is calculated as

Liabilities-to-Assets (Q: Sep. 2023 )=Total Liabilities/Total Assets
=0.666/9.584
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InVivo Therapeutics Holdings  (OTCPK:NVIVQ) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


InVivo Therapeutics Holdings Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of InVivo Therapeutics Holdings's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


InVivo Therapeutics Holdings (InVivo Therapeutics Holdings) Business Description

Traded in Other Exchanges
Address
One Kendall Square, Suite B14402, Building 1400 West, 4th Floor, Cambridge, MA, USA, 02139
InVivo Therapeutics Holdings Corp is a research and clinical stage biomaterials and biotechnology company. It focuses on the treatment of spinal cord injury. The company's product pipeline consists of Neuro spinal scaffold and Bioengineered neural trails. The firm has a clinical development program for acute spinal cord injury and a preclinical development program for chronic spinal cord injury.
Executives
Brice Foose 10 percent owner 236 SILENT MEADOW DRIVE, LAKE ST. LOUIS MO 63367
Daniel R Marshak director C/O CAMBREX CORP, ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ 07073
Christina Morrison director ARAMARK, 1101 MARKET STREET, PHILADELPHIA PA 19107
Richard M. Toselli director, officer: CEO and CMO C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Richard Christopher officer: Chief Financial Officer C/O LUCID, INC., 50 METHODIST HILL DR, SUITE 1000, ROCHESTER NY 14623
C Ann Merrifield director
Bob Rosenthal director 20 NEWBURY ST, BOSTON MA 02116
Heather Hamel officer: Chief Legal Officer and GC ONE KENDALL SQUARE, BUILDING 1400 WEST, FLOOR 4, CAMBRIDGE MA 02139
Jeffrey Modestino officer: See Remarks C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14403, CAMBRIDGE MA 02139
Christopher Mcnulty officer: Chief Financial Officer C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Melanie Golarz officer: Interim CFO C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Jeffrey S. Hatfield director 11080 ROSELLE STREET, SAN DIEGO CA 92121
Pamela J Stahl officer: Chief Commercial Officer ONE KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Richard John Roberts director ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Masuoka K. Lorianne officer: Chief Medical Officer C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070